Novartis’ Post

#ADC #antibodydrugconjugate New Phase 3 data evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate, in previously treated locally recurrent or metastatic triple-negative breast cancer First presentation of Phase 2b three-year follow-up data evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab) in patients with high-risk stage III/IV melanoma following complete resection

FDA's Oncology Center of Excellence invites you to a Conversations on Cancer public panel discussion January 10, 2024, with an overview of 2023's oncology drug approvals and an enriching dialogue on cancer innovation with regulators, investigators, patients, and practitioners. Register here: https://lnkd.in/eCsgzQN2 #cancer #drugapprovals

Today we shared new clinical data being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from our ongoing KT-253 Phase 1 oncology trial. KT-253 is a highly potent and selective degrader that targets MDM2, and the findings shared today continue to support our therapeutic hypothesis for MDM2 degradation and the potential to improve the therapeutic index compared to small molecule inhibitors for a variety of cancers. Read the full press release and view the poster here: https://bit.ly/3Ra3X5F #ASCO24 #TPD #ReinventingMedicine

While great strides have been made in diagnosing and treating #breastcancer, there remains an unmet need for additional effective treatment options. #BreastCancerAwarenessMonth is about more than just raising awareness, it’s about taking action. At ORIC, #breastcancer is a key area of focus. We are developing our EGFR/HER2 inhibitor ORIC-114, and our PLK4 inhibitor as potential treatments for breast cancer. Learn more here: https://bit.ly/3ARUtUR #BCAM 

🚀 Exciting News in the World of Antibody Drug Conjugates!🔬 🌟 Dive into the latest edition of ADC Digest for the first week of May 2024, where groundbreaking advancements are illuminating the field of Antibody Drug Conjugates! 💊 Pfizer and Genmab’s ADC Tivdak receive full FDA approval for recurrent or metastatic cervical cancer 💊 AstraZeneca, Daiichi tout Enhertu trial win in earlier, broader HER2-low breast cancer Stay tuned for more updates and breakthroughs in the realm of Antibody-Drug Conjugates! #ADC #MedicalInnovations #CancerResearch #approval #Innovation #ADCnews #CIScientists #Antibodydrugconjugate

The latest safety data, showcased at American Society of Clinical Oncology (ASCO), demonstrate that Pfizer’s PF-07220060 in combination with endocrine therapy was well tolerated by patients with HR+/HER2- metastatic breast cancer, including those who had previously received CDK4/6 inhibitors as well as those who had not. Maximize Your Knowledge with Expert Insights and Detailed Analysis through DelveInsight Business Research LLP's ASCO 2024 Exclusive Coverage! https://lnkd.in/gkfyXpvu #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

A Milestone in Treating Ovarian Cancer: FDA Grants Full Approval to Elahere The FDA has granted full approval to Elahere, an antibody-drug conjugate (ADC), for the treatment of FRα-positive, platinum-resistant ovarian cancer. Elahere is the first and only ADC approved for this indication in the United States. The approval is seen as a significant breakthrough in the field of oncology and offers new hope for patients with this challenging malignancy. The SORAYA trial demonstrated Elahere's anti-tumor activity and tolerability, with 31.7% of patients achieving a confirmed objective response rate. The MIRASOL trial further supported Elahere's efficacy, showing superiority in overall survival and progression-free survival compared to chemotherapy. This approval marks a milestone in the treatment landscape for ovarian cancer and highlights the importance of targeted therapies in addressing unmet medical needs. For more details please click the link! https://lnkd.in/dm_-PYut #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Himmel Pharmaceuticals is preparing Pakistan’s Digital Breast Cancer Awareness Sessions. An interesting conversation among host and the doctor to know about rising numbers of Breast cancer in Pakistan, being highest in Asia. To overcome the fear of stigmatization & feminine sensitivity which limits the choice of treatment & early detection of Breast Cancer lets join hands to create awareness in society because "Early Detection Saves Lives." Watch us Live with Dr. Mehwish Shahzadi on BOL News at 05:45 PM onwards today, Thursday, 12th October 2023 #hertober #himmel #pharmaceuticals #BOLNews

#Melanoma_Cancer_Diagnostics Market Share Expected Huge Growth during 2022-2030 https://lnkd.in/dE8CtT8X The market for #melanoma cancer diagnostics is predicted to grow as the prevalence of melanoma skin #cancer rises. Increased exposure to ultraviolet radiation in factories, the sun, and other places eventually leads to increased melanoma skin cancer instances, propelling the melanoma cancer #diagnostic market forward. Inhalation Sciences Sweden AB Incyte Merck Group Novartis Pierre Fabre Group Amgen Amgen Deutschland AstraZeneca Bristol Myers Squibb Bristol Myers Squibb UK & Ireland Daiichi Sankyo, Inc.

How can we inspire adoption of innovative cancer diagnostics? Communication between industry, pharmaceutical companies, oncologists, and pathologists is key to ensuring rapid tumour diagnosis in breast cancer. And use of MammaTyper® is a way to enable innovation. As Dr Dario DeBiase says, MammaTyper® means you can continue to work well, whilst adding in “another tool to help you provide more reliable results.”  #BreastCancerDiagnosis #CancerInnovation